For the Inventor, By the Inventor

Enter assignee name

Novato, CA, United States of America

Ultragenyx Pharmaceutical Inc.

Patents = 27

Trademarks = 46

Forward Citations = 41

where 'Filed Patents' based on already Granted Patents

where 'Inventors Filed' based on already Granted Patents

46 inventors (with patents filed for the assignee):

Emil D Kakkis (17 out of 44 patents)

Steven Jungles (9 out of 12 patents)

He Zhao (5 out of 34 patents)

4. Javier San Martin (4 out of 4 patents)

5. Tomohiro Sudo (4 out of 4 patents)

6. Gabrielle Morris (4 out of 4 patents)

7. Michael Vellard (4 out of 4 patents)

8. Jeff Grubb (4 out of 4 patents)

9. Yiumo Chan (2 out of 2 patents)

10. Alexandra Trotier-Faurion (2 out of 2 patents)

11. William F Brubaker (2 out of 2 patents)

12. Arjun Natesan (2 out of 2 patents)

13. Paul Lee (2 out of 2 patents)

14. Sharyl Fyffe-Maricich (2 out of 2 patents)

15. David Lapointe (2 out of 6 patents)

27 patents: Sort by Forward Citations

1. 12487152 - Scalable method for producing transfection reagents (2025-12-02),

2. 12358976 - Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d (2025-07-15),

3. 12338450 - Gene therapy constructs for treating Wilson disease (2025-06-24),

4. 12018288 - Engineered producer cell lines and methods of making and using the same (2024-06-25),

5. 11944658 - Methods of heat inactivation of adenovirus (2024-04-02),

6. 11898170 - Cell culture methods involving HDAC inhibitors or rep proteins (2024-02-13),

7. 11795473 - Use of tonicifying agents to enhance recombinant adeno-associated virus yield (2023-10-24),

8. 11771748 - Methods for treating tumor-induced osteomalacia (2023-10-03),

9. 11753369 - Creatine prodrugs, compositions and methods of use thereof (2023-09-12),

10. 11377643 - Therapeutics for glycogen storage disease type III (2022-07-05),

11. 11332438 - Creatine prodrugs, compositions and methods of use thereof (2022-05-17),

12. 11202822 - Methods for treating hypophosphatemic disorders (2021-12-21),

13. 11013774 - Methods of heat inactivation of adenovirus (2021-05-25),

14. 10889607 - Sialic acid analogs (2021-01-12),

15. 10639360 - Methods for treating hypophosphatemic disorders (2020-05-05),

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare and ultra-rare genetic diseases. Their mission is to transform the lives of patients and their families by developing and delivering therapies for these rare disorders. They are committed to advancing novel treatments that address the underlying causes of these diseases, utilizing their expertise in rare disease biology, genetics, and drug development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

27 Patents

#3 in Novato, CA

#2,842 in California

#11,983 in US

#23,242 in the World

Novato, CA, United States of America

Ultragenyx Pharmaceutical Inc.

Forward Citations = 41

46 inventors:

Emil D Kakkis (17 out of 44 patents)

Steven Jungles (9 out of 12 patents)

He Zhao (5 out of 34 patents)

4. Javier San Martin (4 out of 4 patents)

5. Tomohiro Sudo (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…